T-cell immunity to infection with dengue virus in humans

Frontiers in Immunology

Volumn 5, Issue MAR, 2014, Pages

  Weiskopf, Daniela ^a   Sette, Alessandro ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

DENV; HLA; Pathogenesis; Protection; T cells; Vaccines

Indexed keywords

CELL PROTECTION; CELLULAR IMMUNITY; DENGUE VIRUS; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSPOT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HEMORRHAGIC FEVER; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; REVIEW; SEROTYPE; THROMBOCYTOPENIA; VACCINATION;

EID: 84897932252     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00093     Document Type: Review

References (76)

1. Gubler DJ. Aedes aegypti and Aedes aegypti-borne disease control in the 1990s: top down or bottom up. Charles Franklin Craig Lecture. Am J Trop Med Hyg (1989) 40:571-8.
2. Chen R, Vasilakis N. Dengue-quo tu et quo vadis? Viruses (2011) 3:1562-608. doi: 10.3390/v3091562
3. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature (2013) 496:504-7. doi:10.1038/nature12060
4. Frank C, Hohle M, Stark K, Lawrence J. More reasons to dread rain on vacation? Dengue fever in 42 German and United Kingdom Madeira tourists during autumn 2012. Euro Surveill (2013) 18:20446.
5. Adalja AA, Sell TK, Bouri N, Franco C. Lessons learned during dengue outbreaks in the United States, 2001-2011. Emerg Infect Dis (2012) 18:608-14. doi:10.3201/eid1804.110968
6. Bouri N, Sell TK, Franco C, Adalja AA, Henderson DA, Hynes NA. Return of epidemic dengue in the United States: implications for the public health practitioner. Public Health Rep (2012) 127:259-66.
7. WHO. (2009). Dengue Guidelines for Diagnosis, Treatment, Prevention and Control. Geneva: World Health Organization.
8. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis (2004) 189:990-1000. doi:10.1086/382280
9. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol (1984) 120:653-69.
10. Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg (1988) 38:172-80.
11. Rico-Hesse R, Harrison LM, Salas RA, Tovar D, Nisalak A, Ramos C, et al. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology (1997) 230:244-51. doi:10.1006/viro.1997.8504
12. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev (1998) 11:480-96.
13. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol (2002) 10:100-3. doi:10.1016/S0966-842X(01)02288-0
14. Nguyen TP, Kikuchi M, Vu TQ, Do QH, Tran TT, Vo DT, et al. Protective and enhancing HLA alleles, HLA-DRB1*0901 and HLA-A*24, for severe forms of dengue virus infection, dengue hemorrhagic fever and dengue shock syndrome. PLoS Negl Trop Dis (2008) 2:e304. doi:10.1371/journal.pntd.0000304
15. Stephens HA. HLA and other gene associations with dengue disease severity. Curr Top Microbiol Immunol (2010) 338:99-114. doi:10.1007/978-3-642-02215-9_8
16. Fox A, Le NM, Simmons CP, Wolbers M, Wertheim HF, Pham TK, et al. Immunological and viral determinants of dengue severity in hospitalized adults in Hanoi, Viet Nam. PLoS Negl Trop Dis (2011) 5:e967. doi:10.1371/journal.pntd.0000967
17. Shepard DS, Coudeville L, Halasa YA, Zambrano B, Dayan GH. Economic impact of dengue illness in the Americas. Am J Trop Med Hyg (2011) 84:200-7. doi:10.4269/ajtmh.2011.10-0503
18. Shepard DS, Undurraga EA, Halasa YA. Economic and disease burden of dengue in Southeast Asia. PLoS Negl Trop Dis (2013) 7:e2055. doi:10.1371/journal.pntd.0002055
19. Stahl HC, Butenschoen VM, Tran HT, Gozzer E, Skewes R, Mahendradhata Y, et al. Cost of dengue outbreaks: literature review and country case studies. BMC Public Health (2013) 13:1048. doi:10.1186/1471-2458-13-1048
20. Vaughan K, Greenbaum J, Blythe M, Peters B, Sette A. Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology. Viral Immunol (2010) 23:259-84. doi:10.1089/vim.2010.0006
21. Simmons CP, Dong T, Chau NV, Dung NT, Chau TN, Thao Le TT, et al. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J Virol (2005) 79:5665-75. doi:10.1128/JVI.79.9.5665-5675.2005
22. Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, Malasit P, et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci U S A (2010) 107:16922-7. doi:10.1073/pnas.1010867107
23. Weiskopf D, Yauch LE, Angelo MA, John DV, Greenbaum JA, Sidney J, et al. Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. J Immunol (2011) 187:4268-79. doi:10.4049/jimmunol.1101970
24. Rivino L, Kumaran EA, Jovanovic V, Nadua K, Teo EW, Pang SW, et al. Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J Virol (2013) 87:2693-706. doi:10.1128/JVI.02675-12
25. Weiskopf D, Angelo MA, De Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A (2013) 110:E2046-53. doi:10.1073/pnas.1305227110
26. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and-B polymorphism. Immunogenetics (1999) 50:201-12. doi:10.1007/s002510050594
27. Greenbaum J, Sidney J, Chung J, Brander C, Peters B, Sette A. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics (2011) 63:325-35. doi:10.1007/s00251-011-0513-0
28. Middleton D, Menchaca L, Rood H, Komerofsky R. New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens (2003) 61:403-7. doi:10.1034/j.1399-0039.2003.00062.x
29. Tishkoff SA, Reed FA, Friedlaender FR, Ehret C, Ranciaro A, Froment A, et al. The genetic structure and history of Africans and African Americans. Science (2009) 324:1035-44. doi:10.1126/science.1172257
30. McKinney DM, Southwood S, Hinz D, Oseroff C, Arlehamn CS, Schulten V, et al. A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population. Immunogenetics (2013) 65:357-70. doi:10.1007/s00251-013-0684-y
31. Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics (2010) 11:568. doi:10.1186/1471-2105-11-568
32. Halstead SB, Rojanasuphot S, Sangkawibha N. Original antigenic sin in dengue. Am J Trop Med Hyg (1983) 32:154-6.
33. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med (2003) 9:921-7. doi:10.1038/nm887
34. Davenport FM, Hennessy AV, Francis T Jr. Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med (1953) 98:641-56. doi:10.1084/jem.98.6.641
35. Klenerman P, Zinkernagel RM. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature (1998) 394:482-5. doi:10.1038/28860
36. Yachi PP, Ampudia J, Zal T, Gascoigne NR. Altered peptide ligands induce delayed CD8-T cell receptor interaction-a role for CD8 in distinguishing antigen quality. Immunity (2006) 25:203-11. doi:10.1016/j.immuni.2006.05.015
37. Nguyen TH, Lei HY, Nguyen TL, Lin YS, Huang KJ, Le BL, et al. Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis (2004) 189:221-32. doi:10.1086/380762
38. Halstead SB, Lan NT, Myint TT, Shwe TN, Nisalak A, Kalyanarooj S, et al. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis (2002) 8:1474-9. doi:10.3201/eid0812.020170
39. Dung NT, Duyen HT, Thuy NT, Ngoc TV, Chau NV, Hien TT, et al. Timing of CD8+ T cell responses in relation to commencement of capillary leakage in children with dengue. J Immunol (2010) 184:7281-7. doi:10.4049/jimmunol.0903262
40. Loke H, Bethell DB, Phuong CX, Dung M, Schneider J, White NJ, et al. Strong HLA class I-restricted T cell responses in dengue hemorrhagic fever: a double-edged sword? J Infect Dis (2001) 184:1369-73. doi:10.1086/324320
41. Stephens HA, Klaythong R, Sirikong M, Vaughn DW, Green S, Kalayanarooj S, et al. HLA-A and-B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. Tissue Antigens (2002) 60:309-18. doi:10.1034/j.1399-0039.2002.600405.x
42. Sierra B, Alegre R, Perez AB, Garcia G, Sturn-Ramirez K, Obasanjo O, et al. HLA-A,-B,-C, and-DRB1 allele frequencies in Cuban individuals with antecedents of dengue 2 disease: advantages of the Cuban population for HLA studies of dengue virus infection. Hum Immunol (2007) 68:531-40. doi:10.1016/j.humimm.2007.03.001
43. Falcon-Lezama JA, Ramos C, Zuniga J, Juarez-Palma L, Rangel-Flores H, Garcia-Trejo AR, et al. HLA class I and II polymorphisms in Mexican Mestizo patients with dengue fever. Acta Trop (2009) 112:193-7. doi:10.1016/j.actatropica.2009.07.025
44. Appanna R, Ponnampalavanar S, Lum Chai See L, Sekaran SD. Susceptible and protective HLA class 1 alleles against dengue fever and dengue hemorrhagic fever patients in a Malaysian population. PLoS One (2010) 5:e13029. doi:10.1371/journal.pone.0013029
45. Malavige GN, Rostron T, Rohanachandra LT, Jayaratne SD, Fernando N, De Silva AD, et al. HLA class I and class II associations in dengue viral infections in a Sri Lankan population. PLoS One (2011) 6:e20581. doi:10.1371/journal.pone.0020581
46. Remakus S, Sigal LJ. Memory CD8(+) T cell protection. Adv Exp Med Biol (2013) 785:77-86. doi:10.1007/978-1-4614-6217-0_9
47. Sant AJ, McMichael A. Revealing the role of CD4(+) T cells in viral immunity. J Exp Med (2012) 209:1391-5. doi:10.1084/jem.20121517
48. Kurane I, Meager A, Ennis FA. Dengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon gamma production, and cytotoxic activity. J Exp Med (1989) 170:763-75. doi:10.1084/jem.170.3.763
49. Mathew A, Kurane I, Rothman AL, Zeng LL, Brinton MA, Ennis FA. Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a. J Clin Invest (1996) 98:1684-91. doi:10.1172/JCI118964
50. Gagnon SJ, Ennis FA, Rothman AL. Bystander target cell lysis and cytokine production by dengue virus-specific human CD4(+) cytotoxic T-lymphocyte clones. J Virol (1999) 73:3623-9.
51. Livingston PG, Kurane I, Dai LC, Okamoto Y, Lai CJ, Men R, et al. Dengue virus-specific, HLA-B35-restricted, human CD8+ cytotoxic T lymphocyte (CTL) clones. Recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities. J Immunol (1995) 154:1287-95.
52. Hatch S, Endy TP, Thomas S, Mathew A, Potts J, Pazoles P, et al. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis (2011) 203:1282-91. doi:10.1093/infdis/jir012
53. Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, Peters B, et al. A protective role for dengue virus-specific CD8+ T cells. J Immunol (2009) 182:4865-73. doi:10.4049/jimmunol.0801974
54. Yauch LE, Prestwood TR, May MM, Morar MM, Zellweger RM, Peters B, et al. CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol (2010) 185:5405-16. doi:10.4049/jimmunol.1001709
55. Zompi S, Santich BH, Beatty PR, Harris E. Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J Immunol (2012) 188:404-16. doi:10.4049/jimmunol.1102124
56. Zellweger RM, Miller R, Eddy WE, White LJ, Johnston RE, Shresta S. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog (2013) 9:e1003723. doi:10.1371/journal.ppat.1003723
57. Allicock OM, Lemey P, Tatem AJ, Pybus OG, Bennett SN, Mueller BA, et al. Phylogeography and population dynamics of dengue viruses in the Americas. Mol Biol Evol (2012) 29:1533-43. doi:10.1093/molbev/msr320
58. Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, Westaway EG, et al. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol (1989) 70(Pt 1):37-43. doi:10.1099/0022-1317-70-1-37
59. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet (2012) 380:1559-67. doi:10.1016/S0140-6736(12)61428-7
60. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine (2011) 29:7229-41. doi:10.1016/j.vaccine.2011.06.094
61. Halstead SB. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine (2013) 31:4501-7. doi:10.1016/j.vaccine.2013.06.079
62. Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, Nisalak A, et al. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis (1999) 179:755-62. doi:10.1086/314680
63. Mangada MM, Endy TP, Nisalak A, Chunsuttiwat S, Vaughn DW, Libraty DH, et al. Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren. J Infect Dis (2002) 185:1697-703. doi:10.1086/340822
64. Pantaleo G, Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol (2006) 6:417-23. doi:10.1038/nri1840
65. Harari A, Cellerai C, Enders FB, Kostler J, Codarri L, Tapia G, et al. Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc Natl Acad Sci U S A (2007) 104:16233-8. doi:10.1073/pnas.0707570104
66. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, Ambrozak DR, et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med (2007) 204:1405-16. doi:10.1084/jem.20062363
67. Nepom GT. MHC multimers: expanding the clinical toolkit. Clin Immunol (2003) 106:1-4. doi:10.1016/S1521-6616(02)00014-1
68. Mallone R, Nepom GT. MHC class II tetramers and the pursuit of antigen-specific T cells: define, deviate, delete. Clin Immunol (2004) 110:232-42. doi:10.1016/j.clim.2003.11.004
69. Kotturi MF, Swann JA, Peters B, Arlehamn CL, Sidney J, Kolla RV, et al. Human CD8(+) and CD4(+) T cell memory to lymphocytic choriomeningitis virus infection. J Virol (2011) 85:11770-80. doi:10.1128/JVI.05477-11
70. Beverley PC. Immunology of vaccination. Br Med Bull (2002) 62:15-28. doi:10.1093/bmb/62.1.15
71. Appay V, Van Lier RA, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A (2008) 73:975-83. doi:10.1002/cyto.a.20643
72. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol (2004) 22:745-63. doi:10.1146/annurev.immunol.22.012703.104702
73. Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood (2003) 101:2711-20. doi:10.1182/blood-2002-07-2103
74. Papagno L, Spina CA, Marchant A, Salio M, Rufer N, Little S, et al. Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 2:E20. doi:10.1371/journal.pbio.0020020
75. Whitmire JK, Flavell RA, Grewal IS, Larsen CP, Pearson TC, Ahmed R. CD40-CD40 ligand costimulation is required for generating antiviral CD4 T cell responses but is dispensable for CD8 T cell responses. J Immunol (1999) 163:3194-201.
76. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol (2007) 8:239-45. doi:10.1038/ni1443